The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA.
Tài liệu tham khảo
https://www.oncopeptides.com/en/media/press-releases/oncopeptides-withdraws-pepaxto-in-us-scale-down-organization-and-focus-on-rd. Accessed October 27th 2021.
https://www.fda.gov/advisory-committees/advisory-committee-calendar/cancelled-october-28-2021-meeting-oncologic-drugs-advisory-committee-meeting-announcement-10282021. Accessed October 27th 2021.
https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-melphalan-flufenamide-relapsed-or-refractory-multiple-myeloma. Accessed October 27th 2021.
Powell, 2021, The Oncologic Drugs Advisory Committee Votes of April 2021-Implications for the Fate of Accelerated Approval, JAMA Oncol, 10.1001/jamaoncol.2021.3046
Mohyuddin, 2021, Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review, The Lancet Haematology, 8, e299, 10.1016/S2352-3026(21)00024-7
Siegel, 2020, Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure, Br J Haematol, 188, 501, 10.1111/bjh.16213
Ray, 2016, A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells, British Journal of Haematology, 174, 397, 10.1111/bjh.14065
Gill, 2019, A reality check of the accelerated approval of immune-checkpoint inhibitors, Nat Rev Clin Oncol, 16, 656, 10.1038/s41571-019-0260-y
Schjesvold FH, Dimopoulos MA, Delimpasi S, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. Published online January 12, 2022:S2352-3026(21)00381-1. doi:10.1016/S2352-3026(21)00381-1.
Boutron, 2014, Impact of Spin in the Abstracts of Articles Reporting Results of Randomized Controlled Trials in the Field of Cancer: The SPIIN Randomized Controlled Trial, JCO, 32, 4120, 10.1200/JCO.2014.56.7503
Oncopeptides publishes Q3 2021 report. News Powered by Cision. Accessed January 26, 2022. https://news.cision.com/oncopeptides-ab/r/oncopeptides-publishes-q3-2021-report,c3459305.